Amylyx Pharmaceuticals announced positive topline results from the Phase 3 LUCIDITY clinical trial of avexitide for post-bariatric hypoglycemia. The study enrolled 78 participants and met its primary endpoint, demonstrating a 55% reduction in Level 2 and 3 hypoglycemic events compared to placebo (p=0.000003). Avexitide was well-tolerated with no serious adverse events related to treatment. The company plans to submit a New Drug Application to the FDA by the end of 2026, aiming for potential commercialization in 2027 if approved. Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for rare diseases.
